Cialis 36

Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial.
Objectives: To examine the therapeutic effects of tadalafil on erectile dysfunction (ED) at 24 and 36 hours after dosing.
Methods: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 348 men (mean age 57 years) with ED was conducted in Europe and the United States. Patients were stratified by baseline severity of ED using the Erectile Function domain score of the International Index of Erectile Function and then randomly allocated within the severity group to receive tadalafil 20 mg (n = 175) or placebo (n = 173). Subsequently, participants were randomly assigned to two 4-week treatment intervals, during which they were requested to attempt sexual intercourse approximately 24 or 36 hours after tadalafil or placebo dosing. The primary outcome measure was the proportion of successful sexual intercourse attempts (completed to ejaculation) according to patient self-report using the Sexual Encounter Profile diary.
Conclusions: Tadalafil 20 mg is an effective and well-tolerated treatment for ED that has a period of responsiveness of up to 36 hours.
Similar articles.
Eardley I, Gentile V, Austoni E, Hackett G, Lembo D, Wang C, Beardsworth A. Eardley I, et al. BJU Int. 2004 Oct;94(6):871-7. doi: 10.1111/j.1464-410X.2004.05049.x. BJU Int. 2004. PMID: 15476525 Clinical Trial.
Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W, Murphy AM, Beasley CM Jr, Hague JA, Ahuja S. Young JM, et al. J Androl. 2005 May-Jun;26(3):310-8. doi: 10.2164/jandrol.04126. J Androl. 2005. PMID: 15866997 Clinical Trial.
Seftel AD, Wilson SK, Knapp PM, Shin J, Wang WC, Ahuja S. Seftel AD, et al. J Urol. 2004 Aug;172(2):652-7. doi: 10.1097/01.ju.0000132857.39680.ce. J Urol. 2004. PMID: 15247754 Clinical Trial.
Curran M, Keating G. Curran M, et al. Drugs. 2003;63(20):2203-12; discussion 2213-4. doi: 10.2165/00003495-200363200-00004. Drugs. 2003. PMID: 14498756 Review.
Keating GM, Scott LJ. Keating GM, et al. Drugs. 2003;63(23):2673-703. doi: 10.2165/00003495-200363230-00010. Drugs. 2003. PMID: 14636086 Review.
Cited by.
Ahmed MM, Anwer MK, Soliman GA, Aldawsari MF, Mohammed AA, Alshehri S, Ghoneim MM, Alali AS, Alshetaili A, Alalaiwe A, Bukhari SI, Zafar A. Ahmed MM, et al. PeerJ. 2022 May 26;10:e13482. doi: 10.7717/peerj.13482. eCollection 2022. PeerJ. 2022. PMID: 35642201 Free PMC article.
Lee MK, Lee JH, Sohn SY, Lee SY, Jeong TY, Kim SC. Lee MK, et al. Diabetol Metab Syndr. 2022 Apr 21;14(1):56. doi: 10.1186/s13098-022-00825-w. Diabetol Metab Syndr. 2022. PMID: 35449082 Free PMC article.
Cui WS, Guan RL, Lei HE, Liu JH, Wang T, Zhu SN, Yao C, Wang J, Feng YH, Tian L, Xin ZC. Cui WS, et al. Transl Androl Urol. 2021 Aug;10(8):3358-3367. doi: 10.21037/tau-21-441. Transl Androl Urol. 2021. PMID: 34532260 Free PMC article.
Kedia GT, Ückert S, Tsikas D, Becker AJ, Kuczyk MA, Bannowsky A. Kedia GT, et al. J Clin Med. 2020 Sep 16;9(9):2987. doi: 10.3390/jcm9092987. J Clin Med. 2020. PMID: 32947804 Free PMC article. Review.
Goldstein I, Giraldi A, Maculaitis MC, Li VW, Hartzell-Cushanick R, Hassan TA. Goldstein I, et al. Sex Med. 2020 Sep;8(3):338-349. doi: 10.1016/j.esxm.2020.05.001. Epub 2020 Jun 27. Sex Med. 2020. PMID: 32605816 Free PMC article.